Cd19tm1(cre)Cgn/Cd19+ Faslpr/Fastm1Cgn
involves: 129P2/OlaHsd * C57BL/6 * MRL
|
enlarged lymph nodes |
J:114948
|
enlarged spleen |
J:114948
|
Cd19tm1(cre)Cgn/Cd19+ Faslpr/Fastm1Cgn Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL
|
enlarged lymph nodes |
J:114948
|
enlarged spleen |
J:114948
|
increased double-negative T cell number |
J:114948
|
Cd19tm1(cre)Cgn/Cd19+ Fastm1Ach/Fastm1Ach
involves: 129P2/OlaHsd * BALB/c
|
enlarged spleen |
J:123556
|
increased anti-nuclear antigen antibody level |
J:123556
|
increased immunoglobulin level |
J:123556
|
increased lymphocyte cell number |
J:123556
|
Cd19tm1(cre)Cgn/Cd19+ Fastm1Cgn/Fastm1Cgn
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn
|
increased anti-single stranded DNA antibody level |
J:114948
|
Faslpr-cg/Faslpr-cg
CBA/KlJms-Faslpr-cg/J
|
abnormal hypersensitivity reaction |
J:24805,
J:81770
|
abnormal lymph organ size |
J:24805
|
abnormal T cell differentiation |
J:24805
|
autoimmune response |
J:24805,
J:81770
|
enlarged lymph nodes |
J:24805,
J:81770
|
enlarged spleen |
J:24805
|
increased anti-nuclear antigen antibody level |
J:24805
|
increased autoantibody level |
J:81770
|
increased IgG level |
J:24805,
J:81770
|
increased IgM level |
J:24805,
J:81770
|
increased immunoglobulin level |
J:24805
|
increased spleen weight |
J:81770
|
premature death |
J:24805
|
Faslpr/Faslpr
AK.MRL-Faslpr
|
abnormal renal glomerulus morphology |
J:7454
|
enlarged lymph nodes |
J:7454
|
expanded mesangial matrix |
J:7454
|
glomerulonephritis |
J:7454
|
increased anti-double stranded DNA antibody level |
J:7454
|
increased anti-nuclear antigen antibody level |
J:7454
|
increased autoantibody level |
J:7454
|
increased immunoglobulin level |
J:7454
|
increased mesangial cell number |
J:7454
|
lymph node hemorrhage |
J:7454
|
lymph node necrosis |
J:7454
|
renal glomerular immunoglobulin deposits |
J:7454
|
Faslpr/Faslpr
B6.Cg-Apoetm1Unc Faslpr
|
normal
cardiovascular system phenotype |
J:121671
|
Faslpr/Faslpr
B6.MRL-Faslpr
|
abnormal renal glomerulus morphology |
J:7454
|
decreased interleukin-2 secretion |
J:6638
|
enlarged lymph nodes |
J:6638,
J:7454,
J:135036
|
enlarged spleen |
J:135036
|
expanded mesangial matrix |
J:7454
|
glomerulonephritis |
J:7454,
J:135036
|
increased anti-double stranded DNA antibody level |
J:7454
|
increased anti-nuclear antigen antibody level |
J:6638,
J:135036
|
increased autoantibody level |
J:7454,
J:135036
|
increased double-negative T cell number |
J:135036
|
increased immunoglobulin level |
J:7454
|
increased mesangial cell number |
J:7454
|
lymph node hemorrhage |
J:7454
|
lymph node necrosis |
J:7454
|
premature death |
J:6638,
J:7454,
J:135036
|
renal glomerular immunoglobulin deposits |
J:7454,
J:135036
|
Faslpr/Faslpr
B6.MRL-Faslpr/J
|
abnormal hepatocyte morphology |
J:135830
|
abnormal kidney morphology |
J:132217
|
abnormal liver physiology |
J:120559,
J:135830
|
abnormal NK cell physiology |
J:115033
|
abnormal renal glomerulus basement membrane morphology |
J:132217
|
abnormal splenic cell ratio |
J:132217
|
brain inflammation |
J:120427
|
CNS inflammation |
J:120427
|
decreased B cell apoptosis |
J:135830
|
decreased hepatocyte apoptosis |
J:135830
|
demyelination |
J:120427
|
enlarged lymph nodes |
J:119584
|
focal hepatic necrosis |
J:135830
|
increased anti-double stranded DNA antibody level |
J:132217
|
increased anti-histone antibody level |
J:132217
|
increased anti-nuclear antigen antibody level |
J:132217
|
increased anti-single stranded DNA antibody level |
J:132217
|
increased autoantibody level |
J:132217
|
increased follicular B cell number |
J:132217
|
increased immature B cell number |
J:132217
|
increased marginal zone B cell number |
J:132217
|
increased renal glomerulus apoptosis |
J:132217
|
increased splenocyte number |
J:132217
|
increased susceptibility to bacterial infection |
J:136745
|
increased susceptibility to Picornaviridae infection |
J:120427
|
increased transitional stage B cell number |
J:132217
|
lymph node hyperplasia |
J:132217
|
Faslpr/Faslpr
C3.MRL-Faslpr
|
abnormal interleukin level |
J:8267
|
abnormal T cell morphology |
J:8267
|
abnormal T cell physiology |
J:8267
|
abnormal T cell proliferation |
J:8267
|
abnormal vagina weight |
J:114219
|
decreased apoptosis |
J:114219
|
decreased neuron apoptosis |
J:124252
|
normal
endocrine/exocrine gland phenotype |
J:1028
|
lacrimal gland atrophy |
J:1028
|
lacrimal gland inflammation |
J:1028
|
salivary gland inflammation |
J:1028
|
Faslpr/Faslpr
C3.MRL-Faslpr/J
|
abnormal airway responsiveness |
J:106288
|
abnormal B cell activation |
J:7454
|
abnormal renal glomerulus morphology |
J:7454
|
abnormal T cell morphology |
J:7454
|
decreased eosinophil cell number |
J:106288
|
decreased interleukin-2 secretion |
J:7454
|
enlarged lymph nodes |
J:7454
|
expanded mesangial matrix |
J:7454
|
glomerulonephritis |
J:7454
|
normal
immune system phenotype |
J:7454
|
increased anti-double stranded DNA antibody level |
J:7454
|
increased anti-nuclear antigen antibody level |
J:7454
|
increased apoptosis |
J:106288
|
increased autoantibody level |
J:7454
|
increased immunoglobulin level |
J:7454
|
increased mesangial cell number |
J:7454
|
lymph node hemorrhage |
J:7454
|
lymph node hyperplasia |
J:7454
|
lymph node necrosis |
J:7454
|
normal
mortality/aging |
J:120650
|
premature death |
J:7454
|
renal glomerular immunoglobulin deposits |
J:7454
|
Faslpr/Faslpr
involves: 129P2/OlaHsd * MRL
|
abnormal kidney morphology |
J:45448
|
abnormal renal glomerulus morphology |
J:45448
|
enlarged lymph nodes |
J:26250
|
glomerulonephritis |
J:45448
|
increased blood urea nitrogen level |
J:45448
|
increased double-negative T cell number |
J:26250
|
increased gamma-delta T cell number |
J:26250
|
increased urine protein level |
J:45448
|
kidney inflammation |
J:45448
|
premature death |
J:26250
|
Faslpr/Faslpr
involves: C3H * MRL/Mp
|
abnormal stria vascularis morphology |
J:1060,
J:34296
|
abnormal stria vascularis vasculature morphology |
J:34296
|
autoimmune response |
J:1060
|
increased anti-nuclear antigen antibody level |
J:34296
|
increased or absent threshold for auditory brainstem response |
J:1060,
J:34296
|
increased spleen weight |
J:34296
|
increased susceptibility to systemic lupus erythematosus |
J:34296
|
increased susceptibility to type III hypersensitivity reaction |
J:34296
|
Faslpr/Faslpr
involves: C57BL/6 * MRL/Mp
|
enlarged spleen |
J:73396
|
increased anti-double stranded DNA antibody level |
J:73396
|
increased anti-single stranded DNA antibody level |
J:73396
|
increased IgA level |
J:73396
|
increased IgG1 level |
J:73396
|
increased IgG2a level |
J:73396
|
increased IgG2b level |
J:73396
|
increased IgG3 level |
J:73396
|
increased IgM level |
J:73396
|
lymph node hyperplasia |
J:73396
|
Faslpr/Faslpr
involves: MRL/Mp
|
decreased macrophage apoptosis |
J:154647
|
increased susceptibility to bacterial infection |
J:50903
|
increased susceptibility to induced morbidity/mortality |
J:50903
|
Faslpr/Faslpr
MRL-Faslpr
|
abnormal T-helper 2 physiology |
J:6257
|
enlarged lymph nodes |
J:126261
|
glomerulonephritis |
J:126261
|
increased anti-double stranded DNA antibody level |
J:126261
|
increased anti-nuclear antigen antibody level |
J:126261
|
increased blood urea nitrogen level |
J:126261
|
increased IgG level |
J:126261
|
increased IgM level |
J:126261
|
increased immunoglobulin level |
J:6257
|
increased spleen weight |
J:126261
|
vascular inflammation |
J:126261
|
Faslpr/Faslpr
MRL.Cg-Irf1tm1Mak Faslpr
|
abnormal skin condition |
J:114771
|
epidermal necrosis |
J:114771
|
glomerulonephritis |
J:114771
|
increased anti-double stranded DNA antibody level |
J:114771
|
increased urine protein level |
J:114771
|
kidney failure |
J:114771
|
premature death |
J:114771
|
renal glomerular immunoglobulin deposits |
J:114771
|
skin lesions |
J:114771
|
Faslpr/Faslpr
MRL.Cg-Tnfrsf9tm1Byk Faslpr
|
premature death |
J:127197
|
skin lesions |
J:127197
|
Faslpr/Faslpr
MRL/Mp-Agtpbp1atms Faslpr
|
enlarged lymph nodes |
J:103944
|
enlarged spleen |
J:103944
|
enlarged thymus |
J:103944
|
increased body weight |
J:103944
|
increased tumor incidence |
J:103944
|
ruffled hair |
J:103944
|
Faslpr/Faslpr
MRL/Mp-Faslpr
|
abnormal B cell morphology |
J:108760
|
abnormal B cell receptor editing |
J:131138
|
abnormal cardiovascular system physiology |
J:27634
|
abnormal circulating protein level |
J:27634
|
abnormal coronary artery morphology |
J:27634
|
abnormal cytotoxic T cell physiology |
J:7488
|
abnormal gland morphology |
J:18512
|
abnormal glomerular capillary endothelium morphology |
J:28885
|
abnormal glomerular capillary morphology |
J:28885
|
abnormal immune system organ morphology |
J:28885
|
abnormal immune system physiology |
J:28885
|
abnormal interleukin level |
J:8267
|
abnormal lymph node cell ratio |
J:6257
|
abnormal lymph node morphology |
J:27634
|
abnormal marginal zone B cell morphology |
J:131138
|
abnormal submandibular gland morphology |
J:18512
|
abnormal T cell morphology |
J:8267,
J:108760
|
abnormal T cell physiology |
J:8267
|
abnormal T cell proliferation |
J:8267
|
abnormal T-helper 2 physiology |
J:6257
|
abnormal thymus medulla morphology |
J:28885
|
abnormal thyroid follicle morphology |
J:28171
|
abnormal thyroid gland morphology |
J:28171
|
abnormal type III hypersensitivity reaction |
J:28885
|
blood vessel inflammation |
J:28885
|
decreased interleukin-2 secretion |
J:6638,
J:7488
|
normal
endocrine/exocrine gland phenotype |
J:18512
|
enlarged lymph nodes |
J:13757,
J:27634,
J:28885,
J:108760
|
enlarged Peyer's patches |
J:28885
|
enlarged spleen |
J:28885
|
enlarged thymus |
J:13757
|
glomerular crescent |
J:28885
|
glomerulonephritis |
J:13757,
J:27634,
J:28885
|
increased anti-double stranded DNA antibody level |
J:6257,
J:27634,
J:131138
|
increased anti-erythrocyte antigen antibody level |
J:27634
|
increased anti-nuclear antigen antibody level |
J:27634,
J:28885
|
increased anti-single stranded DNA antibody level |
J:27634
|
increased autoantibody level |
J:28885
|
increased circulating serum albumin level |
J:28885
|
increased circulating total protein level |
J:28885
|
increased IgA level |
J:28885
|
increased IgG1 level |
J:13757,
J:28885
|
increased IgG2a level |
J:13757,
J:28885
|
increased IgG2b level |
J:28885
|
increased IgG level |
J:27634
|
increased IgM level |
J:28885
|
increased immunoglobulin level |
J:6257,
J:13757,
J:28885
|
increased kidney cell proliferation |
J:27634
|
increased mesangial cell number |
J:28885
|
increased renal glomerulus basement membrane thickness |
J:28885
|
increased susceptibility to autoimmune disorder |
J:108760
|
increased thymus weight |
J:28885
|
increased urine protein level |
J:28885
|
joint swelling |
J:27634
|
lacrimal gland inflammation |
J:18512
|
lymph node hemorrhage |
J:27634
|
lymph node hyperplasia |
J:27634
|
lymph node necrosis |
J:27634
|
premature death |
J:13757,
J:27634,
J:28885
|
renal cast |
J:28885
|
renal glomerular immunoglobulin deposits |
J:13757,
J:27634
|
renal glomerular protein deposits |
J:27634
|
salivary gland inflammation |
J:18512
|
skin lesions |
J:28885
|
submandibular gland inflammation |
J:21965
|
thymus atrophy |
J:27634
|
thymus cortex atrophy |
J:13757,
J:28885
|
thyroid gland inflammation |
J:28171
|
Faslpr/Faslpr
MRL/MpJ-Faslpr
|
abnormal leukocyte adhesion |
J:126009
|
abnormal leukocyte morphology |
J:126009
|
autoimmune response |
J:125114
|
blood vessel inflammation |
J:137066
|
decreased activated T cell number |
J:137066
|
decreased B cell number |
J:137066
|
decreased CD4-positive, alpha-beta T cell number |
J:137066
|
decreased CD8-positive, alpha-beta T cell number |
J:137066
|
enlarged lymph nodes |
J:137066
|
enlarged spleen |
J:137066
|
glomerulonephritis |
J:125114,
J:132514,
J:137066
|
impaired leukocyte tethering or rolling |
J:126009
|
increased anti-nuclear antigen antibody level |
J:137066
|
increased autoantibody level |
J:137066
|
increased double-negative T cell number |
J:137066
|
increased immunoglobulin level |
J:125114
|
premature death |
J:125114,
J:137066
|
renal glomerular immunoglobulin deposits |
J:125114
|
Faslpr/Faslpr
MRL/MpJ-Faslpr/J
|
abnormal conjunctival epithelium morphology |
J:123192
|
abnormal enzyme/coenzyme activity |
J:109815
|
abnormal immunoglobulin level |
J:122315
|
abnormal kidney physiology |
J:127199
|
abnormal myocardium layer morphology |
J:14151
|
abnormal renal glomerulus morphology |
J:7454,
J:127199
|
abnormal spatial learning |
J:14151
|
abnormal stria vascularis morphology |
J:3638
|
abnormal strial intermediate cell morphology |
J:3638
|
albuminuria |
J:122315
|
CNS inflammation |
J:14151
|
conjunctivitis |
J:123192
|
cortical renal glomerulopathies |
J:122315
|
decreased IgG level |
J:122315
|
decreased immature B cell number |
J:122315
|
decreased marginal zone B cell number |
J:122315
|
decreased mature B cell number |
J:122315
|
decreased spleen germinal center number |
J:122315
|
decreased transitional stage B cell number |
J:122315
|
dilated renal glomerular capsule |
J:122315
|
enlarged lymph nodes |
J:7454,
J:92084
|
expanded mesangial matrix |
J:127199
|
glomerular crescent |
J:122315
|
glomerulonephritis |
J:7454,
J:92084,
J:122315,
J:127199
|
impaired coordination |
J:14151
|
increased anti-double stranded DNA antibody level |
J:7454,
J:92084,
J:122315
|
increased anti-nuclear antigen antibody level |
J:7454,
J:14151,
J:92084,
J:111811
|
increased autoantibody level |
J:14151,
J:92084
|
increased IgG level |
J:92084
|
increased immunoglobulin level |
J:7454,
J:122315
|
increased mesangial cell number |
J:127199
|
increased neutrophil cell number |
J:127199
|
increased or absent threshold for auditory brainstem response |
J:3638
|
increased plasma cell number |
J:122315
|
increased susceptibility to systemic lupus erythematosus |
J:92084
|
increased urine protein level |
J:92084,
J:122315
|
lymph node hemorrhage |
J:7454
|
lymph node necrosis |
J:7454
|
podocyte foot process effacement |
J:127199
|
premature death |
J:7454
|
renal glomerulus hypertrophy |
J:122315
|
salivary gland inflammation |
J:92084
|
vascular inflammation |
J:127199
|
normal
vision/eye phenotype |
J:123192
|
Faslpr/Faslpr
NOD.MRL(B6)-Faslpr
|
decreased susceptibility to autoimmune diabetes |
J:64051
|
Faslpr/Faslpr
NOD.MRL-Faslpr
|
decreased susceptibility to autoimmune diabetes |
J:78679
|
Faslpr/Fastm1.1Cgn
involves: C57BL/6 * MRL
|
abnormal immune system morphology |
J:114948
|
enlarged lymph nodes |
J:114948
|
enlarged spleen |
J:114948
|
Faslpr/Fastm1Cgn Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2 * MRL
|
enlarged lymph nodes |
J:114948
|
enlarged spleen |
J:114948
|
increased double-negative T cell number |
J:114948
|
Fasm1Btlr/Fasm1Btlr
C57BL/6J-Fasm1Btlr
|
decreased CD4-positive, alpha-beta T cell number |
J:216052
|
decreased CD8-positive, alpha-beta T cell number |
J:216052
|
increased neutrophil cell number |
J:216052
|
increased NK cell number |
J:216052
|
Fasm2Btlr/Fasm2Btlr
C57BL/6J-Fasm2Btlr
|
increased central memory CD4-positive, alpha-beta T cell number |
J:271891
|
increased effector memory CD4-positive, alpha-beta T cell number |
J:271891
|
Fastheo/Fastheo
either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu)
|
enlarged lymph nodes |
J:104190
|
increased anti-nuclear antigen antibody level |
J:104190
|
Fastm1.1(ALPP)Chnd/Fastm1.1(ALPP)Chnd
involves: C57BL/6 * SJL
|
no abnormal phenotype detected |
J:101977
|
Fastm1.1Cgn/Fastm1.1Cgn
involves: C57BL/6
|
abnormal immune system morphology |
J:114948
|
enlarged lymph nodes |
J:114948
|
enlarged spleen |
J:114948
|
Fastm1Ach/Fastm1Ach Tg(GZMB-cre)1Jcb/?
involves: C57BL/6 * FVB/N
|
increased anti-nuclear antigen antibody level |
J:123556
|
increased double-positive T cell number |
J:123556
|
Fastm1Ach/Fastm1Ach Tg(Itgax-cre,-EGFP)4097Ach/?
Not Specified
|
abnormal liver morphology |
J:123556
|
abnormal spleen morphology |
J:123556
|
abnormal spleen periarteriolar lymphoid sheath morphology |
J:123556
|
decreased apoptosis |
J:123556
|
enlarged spleen |
J:123556
|
increased anti-nuclear antigen antibody level |
J:123556
|
increased dendritic cell number |
J:123556
|
increased IgG level |
J:123556
|
increased IgM level |
J:123556
|
increased immunoglobulin level |
J:123556
|
Fastm1Ach/Fastm1Ach Tg(Lck-cre)548Jxm/?
involves: C57BL/6 * CBA
|
increased anti-nuclear antigen antibody level |
J:123556
|
increased double-positive T cell number |
J:123556
|
Fastm1Cgn/Fastm1Cgn
C57BL/6-Fastm1Cgn
|
normal
immune system phenotype |
J:114948
|
Fastm1Cgn/Fastm1Cgn Cd19tm1(cre)Cgn/Cd19+ Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn
|
increased anti-single stranded DNA antibody level |
J:114948
|
Fastm1Cgn/Fastm1Cgn Mogtm1(cre)Gkl/Mog+
involves: C57BL/6
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:114741
|
normal
immune system phenotype |
J:114741
|
Fastm1Cgn/Fastm1Cgn Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn
|
abnormal immune system cell morphology |
J:114948
|
abnormal immune system organ morphology |
J:114948
|
abnormal thymus involution |
J:114948
|
alveolitis |
J:114948
|
decreased B cell number |
J:114948
|
decreased T cell number |
J:114948
|
enlarged spleen |
J:114948
|
increased activated T cell number |
J:114948
|
increased anti-single stranded DNA antibody level |
J:114948
|
increased double-negative T cell number |
J:114948
|
increased inflammatory response |
J:114948
|
increased memory T cell number |
J:114948
|
increased T cell apoptosis |
J:114948
|
kidney inflammation |
J:114948
|
liver inflammation |
J:114948
|
lung inflammation |
J:114948
|
lymph node hypoplasia |
J:114948
|
premature death |
J:114948
|
pulmonary fibrosis |
J:114948
|
spleen hypoplasia |
J:114948
|
weight loss |
J:114948
|
Fastm1Cgn/Fastm1Cgn Tg(Lck-cre)I57Jxm/0
B6.Cg-Fastm1Cgn Tg(Lck-cre)I57Jxm
|
lymph node hypoplasia |
J:114948
|
Fastm1Cgn/Fastm1Cgn Tg(Mx1-cre)1Cgn/0
B6.Cg-Fastm1Cgn Tg(Mx1-cre)1Cgn
|
abnormal immune system morphology |
J:114948
|
enlarged lymph nodes |
J:114948
|
enlarged spleen |
J:114948
|
Fastm1Dlo/Fastm1Dlo
involves: 129P2/OlaHsd * C57BL/6
|
abnormal apoptosis |
J:90750
|
abnormal thymus involution |
J:90750
|
enlarged lymph nodes |
J:31847
|
enlarged spleen |
J:31847
|
increased immunoglobulin level |
J:31847
|
Fastm1Osa/Fastm1Osa
involves: 129P2/OlaHsd * C57BL/6
|
abnormal hepatocyte morphology |
J:64296
|
abnormal hypersensitivity reaction |
J:32125,
J:64296
|
abnormal lymph organ size |
J:64296
|
abnormal T cell clonal deletion |
J:32125
|
enlarged lymph nodes |
J:32125,
J:64296
|
enlarged spleen |
J:32125,
J:64296
|
increased anti-double stranded DNA antibody level |
J:32125
|
increased anti-single stranded DNA antibody level |
J:32125
|
increased autoantibody level |
J:32125
|
increased B cell number |
J:32125
|
increased IgG1 level |
J:32125
|
increased IgG2a level |
J:32125
|
increased IgG2b level |
J:32125
|
increased IgG3 level |
J:32125
|
increased IgG level |
J:32125
|
increased leukocyte cell number |
J:32125
|
increased lymphocyte cell number |
J:32125,
J:64296
|
increased susceptibility to parasitic infection |
J:81397
|
liver hyperplasia |
J:64296
|
lymphoid hyperplasia |
J:64296
|
premature death |
J:64296
|